1
|
Patır P, Önkibar N, Subari S, Eşkazan AE. Plasma cell-directed therapy strategies in immune-mediated thrombotic thrombocytopenic purpura (iTTP). Transfusion 2024; 64:536-545. [PMID: 38235916 DOI: 10.1111/trf.17716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 12/14/2023] [Accepted: 12/17/2023] [Indexed: 01/19/2024]
Affiliation(s)
- Püsem Patır
- Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Nurtaç Önkibar
- Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
| | - Sedef Subari
- Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
| | - Ahmet Emre Eşkazan
- Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
| |
Collapse
|
3
|
Maschan A, Petrova U, Kalinina I, Kurnikova E, Fedorova D, Baidildina D, Kotskaya N, Avdonin P, Novichkova G. Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases. Pediatr Blood Cancer 2021; 68:e28818. [PMID: 33211391 DOI: 10.1002/pbc.28818] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 11/03/2020] [Accepted: 11/04/2020] [Indexed: 11/08/2022]
Affiliation(s)
- Alexey Maschan
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Uliana Petrova
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Irina Kalinina
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Elena Kurnikova
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Daria Fedorova
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Dina Baidildina
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Natalia Kotskaya
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Pavel Avdonin
- Koltsov Institute of Developmental Biology RAS, Moscow, Russia
| | - Galina Novichkova
- Dmitri Rogachev National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| |
Collapse
|
4
|
Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med 2019; 45:1518-1539. [PMID: 31588978 DOI: 10.1007/s00134-019-05736-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 08/07/2019] [Indexed: 12/11/2022]
Abstract
Thrombotic thrombocytopenic purpura (TTP) is fatal in 90% of patients if left untreated and must be diagnosed early to optimize patient outcomes. However, the very low incidence of TTP is an obstacle to the development of evidence-based clinical practice recommendations, and the very wide variability in survival rates across centers may be partly ascribable to differences in management strategies due to insufficient guidance. We therefore developed an expert statement to provide trustworthy guidance about the management of critically ill patients with TTP. As strong evidence was difficult to find in the literature, consensus building among experts could not be reported for most of the items. This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed drug caplacizumab, whose benefits will be maximized if the other components of the management strategy follow a standardized pattern. Finally, unanswered questions are identified as topics of future research on TTP.
Collapse
Affiliation(s)
- Elie Azoulay
- Centre National Maladie rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France.
| | - Philippe R Bauer
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
| | - Eric Mariotte
- Centre National Maladie rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France
| | - Lene Russell
- Department of Intensive Care, Copenhagen University Hospital, RigshospitaletCopenhagen Academy for Medical Simulation and Education, University of Copenhagen, and the Capital Region of Denmark, Copenhagen, Denmark
| | - Paul Knoebl
- Division of Hematology and Hemostasis Department of Medicine 1, Medical University of Vienna, Vienna, Austria
| | - Ignacio Martin-Loeches
- Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, St James Street, Dublin 8, Ireland
| | - Frédéric Pène
- Centre National Maladie Rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, Cochin Hospital and Paris University, Paris, France
| | - Kathryn Puxty
- Department of Intensive Care, Glasgow Royal Infirmary, Glasgow, UK
| | - Pedro Povoa
- Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier, Lisbon, Portugal.,NOVA Medical School, New University of Lisbon, Lisbon, Portugal.,Center for Clinical Epidemiology and Research, Unit of Clinical Epidemiology, Odense University Hospital Odense, Odense, Denmark
| | - Andreas Barratt-Due
- Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway
| | - Jose Garnacho-Montero
- Intensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain
| | | | - Laveena Munshi
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada
| | | | - Michael von Bergwelt-Baildon
- Intensive Care in Hematologic and Oncologic Patients, Munich, Germany.,Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, Germany
| | - Marco Maggiorini
- Medical Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland
| | - Paul Coppo
- Centre National Maladie Rare des Microangiopathies Thrombotiques, Service d'Hématologie, Saint-Antoine Hospital and Paris University, Paris, France
| | - Spero Cataland
- Department of Medicine, Ohio State University, Columbus, OH, USA
| | - Agnès Veyradier
- Centre National Maladies Rares des Microangiopathies Thrombotiques, Service d'Hématologie, Lariboisière Hospital and Paris University, Paris, France
| | - Andry Van de Louw
- Division of Pulmonary and Critical Care, Penn State University College of Medicine, Hershey, PA, USA
| | | |
Collapse
|